Publications

IAS-LAB PUBLICATIONS

Clear

We describe a systematic way of the generalization, to models with nonlinear duality, of the space-time covariant and duality-invariant formulation of duality-symmetric theories in which the covariance of the action is ensured by the presence of a single auxiliary scalar field. It is shown that the duality-symmetric action should be invariant under the two local symmetries characteristic of this approach, which impose constraints on the form of the action similar to those of Gaillard and Zumino and in the noncovariant formalism. We show that the (twisted) self-duality condition obtained from this action upon integrating its equations of motion can always be recast in a manifestly covariant form which is independent of the auxiliary scalar and thus corresponds to the conventional on-shell duality-symmetric covariant description of the same model. Supersymmetrization of this construction is briefly discussed. © 2012 American Physical Society.

Authors: repository Covariant actions for models with nonlinear twisted self-duality; 2012 Dipartimento Fis Galileo Galilei; Sez Padova; Dipartimento Fis Galileo Galilei

Journal: Covariant actions for models with nonlinear twisted self-duality

Published: Pasti, P; Sorokin, D; Tonin, M;

DOI: false

WOS.SCI

Volume: https://arxiv.org/pdf/1205.4243 Pages: 120600194||120600194-green

Keywords: 2012

Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P = 0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P = 0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P = 0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P = 0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).

Authors: publisher N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia; 2012 Populat Hlth Res Inst; Populat Hlth Res Inst

Journal: n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia

Published: Bosch, J; Gerstein, HC; Dagenais, GR; Díaz, R; Dyal, L; Jung, H; Maggiono, AP; Probstfield, J; Ramachandran, A; Riddle, MC; Rydén, LE; Yusuf, S;

DOI: false

WOS.SCI

Volume: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1203859?articleTools=true

Keywords: 2012

5

Authors: publisher Achromic superficial spreading melanoma accidentally treated with imiquimod; 2012 Dermatol Unit; Pathol Unit; Dermatol Unit

Journal: cc-by-nc

Published: Zattra, E; Salmaso, R; Tonin, E; Alaibac, M;

DOI: true

WOS.SCI

Volume: https://medicaljournalssweden.se/actadv/article/download/8797/12278 Pages: 103061702||103061986||103061702-gold

Keywords: 2012

The objective of this study was to describe a large Italian cohort of patients with late-onset glycogen storage disease type 2 (GSDII) at various stages of disease progression and to evaluate the clinical effectiveness of alglucosidase alpha enzyme replacement therapy (ERT). Previous studies showed in late-onset patients ERT efficacy against placebo and variable response in uncontrolled studies. Seventy-four juvenile or adult GSDII patients were treated with ERT in a multicenter open label, non-randomized study, from 12 months up to 54 months. Recombinant human alpha glucosidase (rh-GAA) was injected by intravenous route at 20 mg/kg every second week. Patients were divided into three groups according to ERT duration: Group A received treatment for 12-23 months (n = 16), Group B for 24-35 months (n = 14), and Group C for more than 36 months (n = 44). Clinical assessment included a 6-min walk test (6MWT), forced vital capacity (FVC), the Walton and Gardner-Medwin score, the number of hours of ventilation, body mass index, echocardiography and blood creatine kinase (CK). Included in our cohort were 33 males and 41 females (M:F = 0.8:1), with a mean age at first symptoms of 28.3 years (range 2-55 years) and a mean age of 43 years at study entry (range 7-72 years). Seven wheelchair bound patients, as well as 27 patients requiring ventilation support, were included. After treatment we could observe an increase in distance walked on the 6MWT in the large majority of patients (48/58; 83%), with an overall mean increase of 63 m (from 320 ± 161 to 383 ± 178 m). After treatment in the majority of patients FVC was improved or unchanged (45/69; 65%). In ventilated patients we observed an improvement in average number of hours off the ventilator (from 15.6 to 12.1 h). Six patients stopped mechanical ventilation and two others started it. The effect of therapy was not related to ERT duration. Nine of 64 patients (13%) that underwent to echocardiography showed a variable degree of cardiac hypertrophy (left ventriculum or septum), and a positive effect was observed after 36 months of ERT in one adult case. Discontinuation of treatment occurred in four patients: one drop-off case, one patient died for a sepsis after 34 months of treatment and two patients stopped ERT for worsening of general clinical condition. Mild adverse effects were observed in four cases (5%). This study represents the largest cohort of late-onset GSDII patients treated with ERT, and confirm a positive effect of treatment. These results, obtained in a large case series on therapy, indicate a favourable effect of ERT therapy, even in more advanced stage of the disease. © Springer-Verlag 2011.

Authors: repository Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years; 2012 Dept Neurosci; Dept Neurosci; Dept Neurol Sci; Reg Coordinat Ctr Rare Dis; Dept Neurol; Sect Neuromuscular Dis & Neuropathies; Neurol Unit; Inst Biomed & Mol Immunol; Dept Neurol Sci & Vis; Rare Metab Dis Unit; Immunol & Muscular Pathol Unit; Neuromuscular Unit; Dept Neurosci Psychiat & Anaesthesiol; Neurol Inst; Clin Pediat Neurol; Dept Med Endocrinol Metab & Geriatr

Journal: other-oa

Published: Angelini, C; Semplicini, C; Ravaglia, S; Bembi, B; Servidei, S; Pegoraro, E; Moggio, M; Filosto, M; Sette, E; Crescimanno, G; Tonin, P; Parini, R; Morandi, L; Marrosu, G; Greco, G; Musumeci, O; Di Iorio, G; Siciliano, G; Donati, MA; Carubbi, F; Ermani, M; Mongini, T; Toscano, A;

DOI: false

WOS.SCI

Volume: http://hdl.handle.net/11584/235692 Pages: 113777717||106171087||104623433||113267986||113699233||126351271||104075477||104638897||105514465||103893887||104639508||110467094||113142508||113142508||109503876||104458874||105861393||113953226||113699239||113699239||104623433||113267986||113267986||126351271||105514465||103893887||104639508||110151997||113142508||105861393||104458874||109503876||113953226-green

Keywords: 2012

5

Journal: other-oa

DOI: false

WOS.SCI

Keywords: 2012

5

Authors: publisher A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation; 2012 Dept Pathol; Dept Pathol; Nanotechnol Unit

Journal: A "Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation

Published: Piccinin, S; Tonin, E; Sessa, S; Demontis, S; Rossi, S; Pecciarini, L; Zanatta, L; Pivetta, F; Grizzo, A; Sonego, M; Rosano, C; Dei Tos, AP; Doglioni, C; Maestro, R;

DOI: false

WOS.SCI

Volume: http://www.cell.com/article/S1535610812003510/pdf Pages: 113059652||132406268||113059652||117667633||113059652||132406268-bronze

Keywords: 2012

Fatigue and exercise intolerance are common symptoms of mitochondrial diseases, but difficult to be clinically assessed. New methods to quantify these rather common complaints are strongly needed in the clinical practice. Coenzyme Q10 administration and aerobic exercise may improve exercise intolerance, but more definite studies are still pending. Herein, we have revised ” how to measure” and ” how to treat” these symptoms of mitochondrial patients. Subsequently, we reviewed the clinical data of the 1164 confirmed mitochondrial patients present in the Italian nation-wide database of mitochondrial disease, with special regard to exercise intolerance. We observed that more of 20% of mitochondrial patients complain of exercise intolerance. This symptom seems to be frequently associated with specific patient groups and/or genotypes. Ragged red fibers and COX-negative fibers are more often present in subjects with exercise intolerance, whereas lactate levels could not predict this symptom. Multicenter efforts are strongly needed for rare disorders such as mitochondrial diseases, and may represent the basis for more rigorous longitudinal studies. © 2012 Elsevier B.V.

Authors: publisher Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases; 2012 Neurol Clin; Neurol Clin; IRCCS Ist Sci Neurol; IRCCS Fdn Ca Granda Osped Maggiore Policlin; Neuropediat & Muscle Disorders Unit; Neuromuscular Unit; Inst Neurol; Dept Neurosci Psychiat & Anaestesiol; Fdn Carlo Besta Inst Neurol

Journal: cc-by-nc-nd

Published: Mancuso, M; Angelini, C; Bertini, E; Carelli, V; Comi, GP; Minetti, C; Moggio, M; Mongini, T; Servidei, S; Tonin, P; Toscano, A; Uziel, G; Zeviani, M; Siciliano, G;

DOI: false

WOS.SCI

Volume: http://www.nmd-journal.com/article/S0960896612006219/pdf Pages: 104458839||112781907||113263640||104534016||113263551||113240986||103645252||110185689||104638385||103618674||106952425||103894101||104458839-hybrid

Keywords: 2012

5

Journal: other-oa

DOI: false

WOS.SCI

Keywords: 2012

An 80-year-old woman (PI) has been suffering of late onset progressive weakness and wasting of lower-limb muscles, accompanied by high creatine kinase levels in blood. A muscle biopsy, performed at 63years, showed myopathic features with partial deficiency of cytochrome c oxidase. A second biopsy taken 7years later confirmed the presence of a mitochondrial myopathy but also of vacuolar degeneration and other morphological features resembling inclusion body myopathy. Her 46-year-old daughter (PII) and 50-year-old son (PIII) are clinically normal, but the creatine kinase levels were moderately elevated and the EMG was consistently myopathic in both. Analysis of mitochondrial DNA sequence revealed in all three patients a novel, homoplasmic 15bp tandem duplication adjacent to the 5′ end of mitochondrial tRNA Phe gene, encompassing the first 11 nucleotides of this gene and the four terminal nucleotides of the adjacent D-loop region. Both mutant fibroblasts and cybrids showed low oxygen consumption rate, reduced mitochondrial protein synthesis, and decreased mitochondrial tRNA Phe amount. These findings are consistent with an unconventional pathogenic mechanism causing the tandem duplication to interfere with the maturation of the mitochondrial tRNA Phe transcript. © 2011 Elsevier B.V.

Authors: publisher Partial tandem duplication of mtDNA-tRNA Phe impairs mtDNA translation in late-onset mitochondrial myopathy; 2012 Unit Mol Neurogenet; Unit Mol Neurogenet; Inst Aragones Ciencias Salud; Dipartimento Sci Neurol Neuropsicol Morfol & Moto; Unit Neuromuscular & Neuroinflammatory Disorders

Journal: Partial tandem duplication of mtDNA-tRNAPhe impairs mtDNA translation in late-onset mitochondrial myopathy

Published: Arzuffi, P; Lamperti, C; Fernandez-Vizarra, E; Tonin, P; Morandi, L; Zeviani, M;

DOI: false

WOS.SCI

Volume: http://www.nmd-journal.com/article/S0960896611013137/pdf Pages: 103893881||103893881||108945780||112476963||122023995||103893881-bronze

Keywords: 2012

Recently, several studies have started to explore covert visuospatial attention as a control signal for brain-computer interfaces (BCIs). Covert visuospatial attention represents the ability to change the focus of attention from one point in the space without overt eye movements. Nevertheless, the full potential and possible applications of this paradigm remain relatively unexplored. Voluntary covert visuospatial attention might allow a more natural and intuitive interaction with real environments as neither stimulation nor gazing is required. In order to identify brain correlates of covert visuospatial attention, classical approaches usually rely on the whole α-band over long time intervals. In this work, we propose a more detailed analysis in the frequency and time domains to enhance classification performance. In particular, we investigate the contribution of α sub-bands and the role of time intervals in carrying information about visual attention. Previous neurophysiological studies have already highlighted the role of temporal dynamics in attention mechanisms. However, these important aspects are not yet exploited in BCI. In this work, we studied different methods that explicitly cope with the natural brain dynamics during visuospatial attention tasks in order to enhance BCI robustness and classification performances. Results with ten healthy subjects demonstrate that our approach identifies spectro-temporal patterns that outperform the state-of-the-art classification method. On average, our time-dependent classification reaches 0.74 ± 0.03 of the area under the ROC (receiver operating characteristic) curve (AUC) value with an increase of 12.3% with respect to standard methods (0.65 ± 0.4). In addition, the proposed approach allows faster classification (<1 instead of 3 s), without compromising performances. Finally, our analysis highlights the fact that discriminant patterns are not stable for the whole trial period but are changing over short time intervals. These results support the hypothesis that visual attention information is actually indexed by subject-specific α sub-bands and is time dependent. © 2012 IOP Publishing Ltd.

Authors: publisher Time-dependent approach for single trial classification of covert visuospatial attention; 2012 Chair Noninvas Brain Machine Interface; Chair Noninvas Brain Machine Interface

Journal: Time-dependent approach for single trial classification of covert visuospatial attention

Published: Tonin, L; Leeb, R; Millán, JD;

DOI: false

WOS.SCI

Volume: https://iopscience.iop.org/article/10.1088/1741-2560/9/4/045011/pdf Pages: 109900823||109900823||109900823-bronze

Keywords: 2012

« Previous 1…128 129130131 132…161 Next »

IAS-LAB PUBLICATIONS

Contact